Amanote Research
Register
Sign In
ZW25 Active in HER2-positive Cancers
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-nb2018-162
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
November 30, 2018
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Identification of New miRNA Biomarkers Associated With HER2-positive Breast Cancers
Oncoscience
Cancer Research
Oncology
A Phenotypic and Mechanistic Perspective on Heterogeneity of HER2-positive Breast Cancers
Molecular and Cellular Oncology
Cancer Research
Molecular Medicine
Outcomes of Chemotherapies and HER2 Directed Therapies in Advanced HER2-mutant Lung Cancers
Lung Cancer
Cancer Research
Oncology
Respiratory Medicine
Pulmonary
Intrinsic Molecular Subtypes of Breast Cancers Categorized as HER2-positive Using an Alternative Chromosome 17 Probe Assay
Breast Cancer Research
Cancer Research
Oncology
PB.40. What Happens to the Ductal Carcinoma in Situ in HER2-positive Cancers Treated With Neoadjuvant Chemotherapy and Trastuzumab?
Breast Cancer Research
Cancer Research
Oncology
Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers Treated With Neoadjuvant Chemotherapy
Targeted Oncology
Cancer Research
Oncology
Pharmacology
Adjuvant Treatment of HER2-positive Breast Cancer: Winning Efforts Continue to Improve HER2-positive Patient Outcome Long-Term
Breast Cancer Research
Cancer Research
Oncology
Benefit of Post Mastectomy Radiation Therapy (PMRT) in Node-Positive, HER2-Positive Patients With Breast Cancer Receiving Anti-Her2 Treatments
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro
Journal of Translational Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
